Stock MBIO MINDBIO THERAPEUTICS CORP.
Add to a list
To use this feature you must be a member
Log inSign up

All News MindBio Therapeutics Corp.

Equities

MBIO

CA60256C1086

Market Closed - Canadian Securities Exchange
Other stock markets
 12:47:54 15/06/2024 am IST 		5-day change 1st Jan Change
0.05 CAD 0.00% Intraday chart for MindBio Therapeutics Corp. +11.11% +100.00%
12/06 Mindbio Therapeutics Reports Secondary Data: Improvement of Psychological Outcomes & Safety Results in Depressed Patients from Phase 2A Depression Trial CI
13/05 MindBio Therapeutics Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024 CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
MindBio Therapeutics Reports Secondary Data, Improvement of Psychological Outcomes and Safety Results in Depressed Patients from Phase 2A Depression Trial
AQ
Mindbio Therapeutics Reports Secondary Data: Improvement of Psychological Outcomes & Safety Results in Depressed Patients from Phase 2A Depression Trial
CI
MindBio Therapeutics Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024
CI
MindBio Therapeutics Scientists Present Landmark Women's Health Trials, Company to Release Phase 2A Depression Trial Secondary Data This Month
AQ
Mindbio Therapeutics Corp. Announces Multiple Phase 2B Clinical Trials Underway Supported by Positive Trial Data and Planning for Phase 3
CI
MindBio Therapeutics Announces Landmark Women's Health CNS Drug Trials
AQ
MindBio Therapeutics Corp. Announces the Regulatory Approval of A Series of Clinical Trials in Women's Health Using MB22001
CI
MindBio Landmark Sleep Research Published in Prestigious Nature Portfolio Journal Translational Psychiatry
AQ
MindBio Beginning Landmark Phase 2B Take-Home Microdosing Clinical Trial in Patients with Major Depressive Disorder
MT
MindBio Therapeutics Corp. Begins Phase 2B Take-Home Microdosing Clinical Trial in Patients with Major Depressive Disorder
CI
MindBio Therapeutics Receives Final Approval to Conduct Phase 2B Trial Microdosing Mb22001 in Patients With MDD
MT
Mindbio Therapeutics Receives Final Regulatory Approval to Conduct Phase 2B Randomised Controlled Trial Microdosing Mb22001 in Patients Diagnosed with Major Depressive Disorder
CI
MindBio Therapeutics Announces Positive Depression Data from World-First Phase 2a Take-Home Microdosing Trial
AQ
MindBio Therapeutics Corp. Announces Positive Depression Data from World-First Phase 2a Take-Home Microdosing Trial
CI
MindBio Therapeutics Completes World First Take Home Phase 2a Microdosing Depression Trial
AQ
MindBio Therapeutics Corp. Completes World First Take Home Phase 2a Microdosing Depression Trial
CI
MindBio Therapeutics Corp. Announces Completion of Landmark Phase 2A LSD Microdosing Clinical Trial in Distressive Disorder
CI
MindBio Therapeutics Corp. CEO Provides End of Year Video Update on Phase 2 Clinical Trials
CI
MindBio Therapeutics Corp. Presents World First Phase 2B Take-Home Microdosing Clinical Trial in Cancer
CI
MindBio Therapeutics Corp. Begins Dosing MB22001 in World First Phase 2B Microdosing Clinical Trial in Advanced Stage Cancer Patients
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. MBIO Stock
  4. News MindBio Therapeutics Corp.